Annual Financial Report

RTW Biotech Opportunities Ltd
25 April 2024
 

A green logo on a black background Description automatically generated with medium confidence

 

LEI: 549300Q7EXQQH6KF7Z84

 

25 April 2024

RTW Biotech Opportunities Ltd
Annual Financial Report

 


Year ended 31 December 2023

 

A tagged copy of the above document was submitted to the National Storage Mechanism on 25 April 2024 and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

For Further Information:

 

RTW Investments, LP

+44 (0)20 7959 6361

Woody Stileman, Managing Director

Krisha McCune, Director, Investor Relations

 

 

 

 

About RTW Biotech Opportunities Ltd:

 

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

 

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100